NEORNAT
- Biotech or pharma, therapeutic R&D
NEORNAT Inc. is a biotech company specializing in the development of macrophage-based immunotherapies and first-in-class RNA therapeutics for solid tumors.
Founded in 2020 by Dr. Suk Woo Nam, a leading cancer RNA biologist, NEORNAT is advancing a proprietary RNA platform, NRT-YHD, designed to reprogram tumor-associated macrophages and overcome limitations of conventional antibody therapies such as CD47 blockade.
Its lead asset, NRT-YHD_001, is a liver cancer-specific macrophage activator poised to enter Phase I clinical trials in 2025 following successful IND-enabling studies.
Backed by a full-cycle disease transcriptomic database, robust in vivo imaging systems, and strong academic-industry partnerships, NEORNAT is also developing multiple globally competitive, first-in-class RNA-based immuno-oncology assets targeting various indications. The company has been recognized through national funding programs including TIPS and the Korea Drug Development Fund.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}